Pyragrel Sodium

吡拉格雷钠

Report date: 2023/05/09 20:00:38
NME

Base Information

Drug NamePyragrel Sodium
Drug Alias Name吡拉格雷Tetramethylpyrazine-2'-O-Sodium FerulateMC002TSFMC-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThromboxane A2 synthase inhibitors
TargetsThromboxane A2 synthase
Therapy Area/IndicationsDyskinesiasCerebral Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHefei Industrial Pharmaceutical Co LtdGuangzhou Bo Teng Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Bo Teng Biomedical Technology Co LtdHefei Industrial Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDyskinesiasCerebral Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A